Class Action Filed Against Beta Bionics Over Insulin Pump Allegations

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has announced the filing of a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX), and certain of its officers. The lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired Beta Bionics securities between July 30, 2025, and February 24, 2026.

The complaint alleges that throughout the class period, Beta Bionics made materially false and misleading statements and failed to disclose critical information regarding the company's iLet Bionic Pancreas insulin pump. Specifically, the lawsuit claims that the U.S. Food and Drug Administration (FDA) had identified deficiencies in the company's quality management system, its investigation and correction of known device malfunctions, and its risk analysis for the iLet. Additionally, the complaint states that the company failed to report serious customer complaints that included serious injuries, rather than only minor events requiring no medical intervention. According to the lawsuit, this understatement of the FDA's findings and the safety and regulatory risks affecting the iLet led to misleading positive statements about the safety, efficacy, and commercial prospects of the device and the company as a whole.

The lawsuit asserts that Beta Bionics' failure to disclose these critical issues misled investors and resulted in harm to their financial interests. Investors who purchased or otherwise acquired Beta Bionics securities during the class period are encouraged to visit the firm’s website, bgandg.com/cases/beta-bionics-inc-bbnx-class_action_lawsuit, to learn more about the case and their potential legal rights.

If you are a Beta Bionics investor who purchased or otherwise acquired securities during the class period, you have until November 3, 2026, to request that the Court appoint you as a lead plaintiff. Your ability to share in any recovery does not require you to serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC represents investors in class actions on a contingency fee basis, meaning the firm will seek reimbursement for out-of-pocket expenses and attorneys' fees only if they are successful in the case.

Peretz Bronstein, founding partner of Bronstein, Gewirtz & Grossman, LLC, stated, "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."